Zydus Cadila has received the tentative approval from the United States Food & Drug Administration (USFDA) to market Fingolimod Capsules 0.5 mg, mainly used for treatment of multiple sclerosis. The drug will be produced at the group's formulations manufacturing facility at the pharma SEZ, in Ahmedabad. The estimated sales for Fingolimod Capsules is $2.1 billion, as per IMS MAT May 2017.
The group now has over 120 approvals and has so far filed more than 300 Abbreviated New Drug Applications (ANDAs) since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
